Calliditas Therapeutics AB is a Sweden-based biopharmaceutical company focused on developing and commercializing treatments for rare kidney and liver diseases with significant unmet medical need. Headquartered in Stockholm, the company operates globally through a combination of in-house R&D and strategic partnerships.
Its lead product is Nefecon, a targeted-release formulation of budesonide designed to modulate mucosal immunity in IgA nephropathy (IgAN). Nefecon is marketed as TARPEYO in the United States and as KINPEYGO in the European Union. Calliditas is also advancing setanaxib, an oral NOX1/4 inhibitor, in clinical programs for fibrotic and inflammatory conditions, including primary biliary cholangitis and select oncology settings.
